Results 141 to 150 of about 23,818,397 (163)

Harnessing Open-Source Solutions: Insights From the First Open Systems Pharmacology (OSP) Community Conference. [PDF]

CPT Pharmacometrics Syst Pharmacol
Dallmann A, Feick D, Balazki P, Benamara S, Burghaus R, Chenel M, Choi SL, Cordes H, Guimarães M, Hamadeh A, Ince I, Job KM, Kanacher T, Kovar A, Kuepfer L, Lippert J, Macente J, Nauwelaerts N, Niederalt C, Peters S, Proença S, Sato M, Schaller S, Schlender JF, Schneider A, Sjögren E, Solodenko J, Staab A, Vrenken P, Wendl T, de Witte WEA, Teutonico D.   +31 more
europepmc   +1 more source

Classification system proposed to guide the design, development, regulatory approval, and scaling of long acting, small- and macro-molecule parenteral products (CS-BLAP). [PDF]

J Pharm Sci
Perazzolo S, Shen DD, Ho RJY.
europepmc   +1 more source

Development of a Physiologically Based Pharmacokinetic (PBPK) Simulation Model for Nicotine. [PDF]

Biopharm Drug Dispos
Kim B, Bae SH, Bashar M, Yi B, Rahman MA, Awuah P, Hartog M, Panarsky R, Zhang T.   +8 more
europepmc   +1 more source

Improvement of XZP8257 Dissolution Properties Through Amorphous and Mixed-Phase Precipitate Formation in Biorelevant Media. [PDF]

Biopharm Drug Dispos
Zhang M, Zhang S, Wu B, Zhang Z, Hu Q, Wang L, Liu D.   +6 more
europepmc   +1 more source

Integrating Experimental Physicochemical Data with PBPK Modeling to Guide the Translational Development of the Antifungal 1,3,4-Oxadiazole Derivative LMM6. [PDF]

ACS Omega
Piai JMB, Lippa VNM, Caleffi-Marchesini ER, Borghi Pangoni FB, Felipe MS, Kioshima ES, Diniz A.   +6 more
europepmc   +1 more source

Global Trends in Integrating Machine Learning (ML) with Model-Informed Drug Development (MIDD): A Bibliometric and Systematic Review (2015-2025). [PDF]

Pharmaceutics
Dermawan D, Chtita S, Alotaiq N.
europepmc   +1 more source

Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges. [PDF]

CPT Pharmacometrics Syst Pharmacol
Yates JWT, Zientek M, Taskar KS, Lin W, Heimbach T, Willmann S, Rehmel J, Parrott N, Hanley M, Badee J, Chen Y, Cole S, De Zwart L, Haertter S, Jiang R, Kotsuma M, Liang G, Lin YW, Liu J, Ou Y, Rascher J, Shaik NA, Wahlstrom J, Wang X, Xiao G, Yee KL, Cheung SYA.   +26 more
europepmc   +1 more source

State of Art of Dose Individualization to Support tacrolimus drug monitoring: What's Next? [PDF]

Transpl Int
Lloberas N, Fernández-Alarcón B, Vidal-Alabró A, Colom H.   +3 more
europepmc   +1 more source

Physiologically based biopharmaceutics modeling of regional and colon absorption in humans

European Journal of Pharmaceutics and Biopharmaceutics, 2023
Colon absorption is a key determinant for successful development of extended release and colon targeted drug products. This is the first systematic evaluation of the ability to predict in vivo regional differences in absorption and the extent of colon ...
Patrick F Augustijns, Erik Sjögren, Emma Eckernäs   +2 more
exaly   +2 more sources

Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies

Journal of Pharmaceutical Sciences, 2021
For oral drug products, in vitro dissolution is the most used surrogate of in vivo dissolution and absorption. In the context of drug product quality, safe space is defined as the boundaries of in vitro dissolution, and relevant quality attributes ...
Tausif Ahmed, Sandra Suarez-Sharp, Sivacharan Kollipara   +2 more
exaly   +2 more sources